Sanofi breaks into digital therapeutics with mental health app for MS patients

sanofi
Sanofi and Happify Health have partnered on an app to improve mental health outcomes for people with MS, looking for positive test results before they submit the app to the FDA. (Sanofi)

Sanofi joins the digital therapeutics market Tuesday with a proposed app to improve mental health in patients with multiple sclerosis. Created in partnership with established mental health digital therapeutics firm Happify Health, the app is currently in a proof-of-concept online trial with several thousand MS patients.

After those results, expected later this year, are in, Sanofi and Happify plan to submit the app to the FDA to go through the regulatory process for software as a medical device.

The app is Sanofi’s first proposed digital therapeutic, and the company specifically chose MS as an entry point into the space because of its extensive experience with the condition, Ameet Nathwani, M.D., Sanofi's chief medical officer and chief digital officer, said.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: Sanofi, Google team up in search of new treatments, marketing solutions

Statistics show that people living with MS are two to five times more likely to develop major depression than the general population. The goal of Sanofi, which markets MS drugs Aubagio and Lemtrada, is to not only maximize MS patients’ physical health, but also mental health. 

The base software platform from Happify Health is already used for a non-specific solution in anxiety and depression with four million users. Sanofi worked with Happify to incorporate the specific medical and scientific needs and considerations around MS.

“If you can improve depression and anxiety in a clinically meaningful way in a very robust program, can you in patients with MS also improve some of their underlying MS symptomology? We know there are many relationships,” Nathwani said, adding that the move forward with this digital therapeutic will test “whether there are specific improvement in MS symptoms before making value propositions.”

The timeline for the app depends on the FDA and what level of evidence it will require once Sanofi and Happify submit, he said. However, the FDA has signaled its general willingness to consider and approve digital therapies with its proactive Digital Health Software Precertification (Pre-Cert) Program. The first FDA-approved digital therapeutics was Pear Therapeutics’ reSET app to treat substance abuse, launched in partnership with Novartis' Sandoz last year.

RELATED: Sanofi's new chief digital officer joins wave of executives looking to leverage tech for treatments

While this is Sanofi’s first move into digital therapeutics, it won’t be the last. Nathwani said the company has a list of 10 disease areas it would like to consider.

“This is a first foray, but we’re certainly talking to other companies about digital therapy approaches in other diseases. So yes, we see how this could become more of a portfolio play where we would have a portfolio of digital therapeutics which are clinically meaningful and could be used as prescribed agents,” he said.

Read more on

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.